Skip to main content
. 2022 Mar 16;79(3):191. doi: 10.1007/s00018-022-04219-z

Fig. 4.

Fig. 4

Immunotherapies based on type I IFNs. Type I IFN inducers, including TLR agonists, STING agonists, chemotherapeutics and targeted drugs, radiation therapy, oncolytic viruses, and others, are undergoing preclinical and clinical trials